drugset / Trial / NCT01205269

The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01205269

Phase 2 Completed 28 enrolled AstraZeneca
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to investigate effects of inhaled AZD8683 compared to placebo in COPD patients.

Timeline

Start
2010-10
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD8683 Unknown 50 ug Inhaled
Subject AZD8683 Unknown 200 ug Inhaled